Clinical Trials
96 trialsRIBOLARIS
SOLTI Breast Cancer Research Group
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer
Universitas Airlangga
Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer
Centre Antoine Lacassagne
Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)
M.D. Anderson Cancer Center
STEREO-SEIN
Gustave Roussy, Cancer Campus, Grand Paris
NoCUT-BC
Ohio State University Comprehensive Cancer Center
AKRA
Institute of Oncology Ljubljana
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
Memorial Sloan Kettering Cancer Center
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
Rutgers, The State University of New Jersey
PRADAIIBE
Cancer Research Antwerp
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
First Affiliated Hospital of Zhejiang University
Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
M.D. Anderson Cancer Center
CISN-L
First Affiliated Hospital of Wenzhou Medical University
ISNA-Sein
Institut Bergonié
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
First Affiliated Hospital of Zhejiang University
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
First Affiliated Hospital of Zhejiang University
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
Xijing Hospital
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
First Affiliated Hospital of Zhejiang University
SPORTNATHy
The Greater Poland Cancer Centre
Neoadjuvant Radiotherapy and Immediate Implant-Based Breast Reconstruction
Hubei Cancer Hospital
INFLAMMATE
Federal University of São Paulo
ADAPT
West German Study Group
INDUCE
Japan Breast Cancer Research Group
Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer
Affiliated Hospital of Qinghai University
A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer
Xijing Hospital
Aromatherapy in the Treatment of Early Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
BRENAR
UMC Utrecht
Neoadjuvant Radiotherapy for Breast Cancer
Changhai Hospital
Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy
Dana-Farber Cancer Institute
Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy
Seoul National University Hospital
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Canadian Cancer Trials Group
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
University of Nebraska
BiOnHER
Institut Català d'Oncologia
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Alliance for Clinical Trials in Oncology
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Barbara Ann Karmanos Cancer Institute
LABC
Sunnybrook Health Sciences Centre
The Detection of Cell-in-cell Structure (CICs) in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy
Beijing Shijitan Hospital, Capital Medical University
Neoadjuvant Radiation in Locally Advanced Breast Cancer
Fudan University
Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology
ChineseAMS
Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy
Mansoura University
Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer
Medstar Health Research Institute
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
University of California, San Francisco
Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer
Zhejiang Cancer Hospital
Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
Case Comprehensive Cancer Center
COMPETE
Ruijin Hospital
IMET
Federation of Breast Diseases Societies
IRAM
Institut de Cancérologie de la Loire